Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $3,400 | 1 | 41.5% |
| Consulting Fee | $3,050 | 2 | 37.2% |
| Travel and Lodging | $1,133 | 1 | 13.8% |
| Food and Beverage | $614.06 | 5 | 7.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Veloxis Pharmaceuticals, Inc. | $7,976 | 6 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $101.32 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $85.68 | 1 | $0 (2024) |
| Nevro Corp. | $33.91 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119.59 | 2 | AstraZeneca Pharmaceuticals LP ($85.68) |
| 2023 | $3,151 | 3 | Veloxis Pharmaceuticals, Inc. ($3,050) |
| 2022 | $4,926 | 4 | Veloxis Pharmaceuticals, Inc. ($4,926) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: Spinal Cord Stimulator | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $85.68 | General |
| Category: Respiratory | ||||||
| 06/07/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $101.32 | General |
| Category: CRITICAL CARE | ||||||
| 02/23/2023 | Veloxis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| 01/23/2023 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: TRANSPLANTATION | ||||||
| 09/22/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $123.15 | General |
| Category: Immunosuppresant | ||||||
| 05/19/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Honoraria | Cash or cash equivalent | $3,400.00 | General |
| Category: Immunosuppresant | ||||||
| 05/19/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Travel and Lodging | Cash or cash equivalent | $1,132.71 | General |
| Category: Immunosuppresant | ||||||
| 05/19/2022 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $270.00 | General |
| Category: Immunosuppresant | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 517 | 1,037 | $84,892 | $21,895 |
| 2022 | 8 | 417 | 570 | $90,299 | $22,357 |
| 2021 | 6 | 419 | 462 | $86,259 | $23,895 |
| 2020 | 10 | 591 | 822 | $91,236 | $21,967 |
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 97 | 104 | $27,880 | $5,981 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 83 | $14,762 | $4,003 | 27.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 64 | 64 | $13,120 | $3,838 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 43 | $10,749 | $3,252 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 35 | 36 | $5,865 | $1,283 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $3,720 | $1,108 | 29.8% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 20 | 21 | $2,100 | $1,012 | 48.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 84 | $3,360 | $694.42 | 20.7% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 18 | 23 | $1,725 | $306.86 | 17.8% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 15 | 15 | $450.00 | $243.00 | 54.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 19 | 20 | $200.00 | $68.20 | 34.1% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 11 | 11 | $440.00 | $63.25 | 14.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 54 | 521 | $521.00 | $44.25 | 8.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 139 | 165 | $43,867 | $10,191 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 156 | 184 | $30,176 | $7,128 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 39 | $6,921 | $1,894 | 27.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $4,715 | $1,749 | 37.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 13 | 13 | $975.00 | $552.47 | 56.7% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2022 | 12 | 12 | $1,200 | $365.08 | 30.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 11 | 11 | $1,815 | $354.85 | 19.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 13 | 13 | $520.00 | $112.85 | 21.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 110 | $110.00 | $9.63 | 8.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 115 | 130 | $30,534 | $8,327 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 134 | 153 | $23,420 | $6,243 | 26.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 33 | 38 | $6,698 | $2,260 | 33.7% |
About Mark Dedmon, PA-C
Mark Dedmon, PA-C is a Surgical healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942317938.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Dedmon, PA-C has received a total of $8,197 in payments from pharmaceutical and medical device companies, with $119.59 received in 2024. These payments were reported across 9 transactions from 4 companies. The most common payment nature is "Honoraria" ($3,400).
As a Medicare-enrolled provider, Dedmon has provided services to 1,944 Medicare beneficiaries, totaling 2,891 services with total Medicare billing of $90,114. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Practice Information
- Specialty Surgical
- Location San Antonio, TX
- Active Since 08/24/2006
- Last Updated 07/16/2007
- Taxonomy Code 363AS0400X
- Entity Type Individual
- NPI Number 1942317938
Products in Payments
- Envarsus (Drug) $4,926
- ENVARSUS (Drug) $500.00
- TERLIVAZ (Drug) $101.32
- AIRSUPRA (Drug) $85.68
- Senza (Device) $33.91
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgical Doctors in San Antonio
Lisa Garrison, Pa-C, PA-C
Surgical — Payments: $32,819
Ms. Melinda Gonzalez, P.a.-C, P.A.-C
Surgical — Payments: $4,901
Mr. James Houston, Pa-C, PA-C
Surgical — Payments: $3,556
Mr. Michael Singer, Pa-C, PA-C
Surgical — Payments: $2,506
Heather Haglund, Pa-C, PA-C
Surgical — Payments: $1,877
Zachary Swanson, Physician Assistant, PHYSICIAN ASSISTANT
Surgical — Payments: $1,661